JP2020536971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536971A5 JP2020536971A5 JP2020542056A JP2020542056A JP2020536971A5 JP 2020536971 A5 JP2020536971 A5 JP 2020536971A5 JP 2020542056 A JP2020542056 A JP 2020542056A JP 2020542056 A JP2020542056 A JP 2020542056A JP 2020536971 A5 JP2020536971 A5 JP 2020536971A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- coor
- halogen
- alkyl substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@@]1O[C@@](C*)C(*)C1 Chemical compound C[C@@]1O[C@@](C*)C(*)C1 0.000 description 54
- LKHAPZNNTXNFPN-DPHDGMEMSA-N C#C[C@@H]([C@@H]1OP(OC[C@H]([C@H]([C@H]2F)OP(OC3)(S)=O)O[C@H]2[n]2c(ncnc4N)c4nc2)(S)=O)O[C@H]3[C@H]1O Chemical compound C#C[C@@H]([C@@H]1OP(OC[C@H]([C@H]([C@H]2F)OP(OC3)(S)=O)O[C@H]2[n]2c(ncnc4N)c4nc2)(S)=O)O[C@H]3[C@H]1O LKHAPZNNTXNFPN-DPHDGMEMSA-N 0.000 description 1
- PDPYSCVBTHFLHR-LNCINSFHSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@H](COP(O[C@H]2[C@H](C#Cc3ccccc3)O[C@H](CO3)[C@H]2O)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@H](COP(O[C@H]2[C@H](C#Cc3ccccc3)O[C@H](CO3)[C@H]2O)(S)=O)[C@H]1OP3(S)=O PDPYSCVBTHFLHR-LNCINSFHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572884P | 2017-10-16 | 2017-10-16 | |
| US62/572,884 | 2017-10-16 | ||
| PCT/US2018/056030 WO2019079261A1 (en) | 2017-10-16 | 2018-10-16 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536971A JP2020536971A (ja) | 2020-12-17 |
| JP2020536971A5 true JP2020536971A5 (enExample) | 2021-11-18 |
| JP7254821B2 JP7254821B2 (ja) | 2023-04-10 |
Family
ID=64110154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542056A Active JP7254821B2 (ja) | 2017-10-16 | 2018-10-16 | 抗がん剤としての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11427610B2 (enExample) |
| EP (1) | EP3697801B1 (enExample) |
| JP (1) | JP7254821B2 (enExample) |
| KR (1) | KR102747388B1 (enExample) |
| CN (1) | CN111406063B (enExample) |
| ES (1) | ES2997757T3 (enExample) |
| WO (1) | WO2019079261A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660311B2 (en) | 2017-10-10 | 2023-05-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| JP7250808B2 (ja) * | 2018-03-08 | 2023-04-03 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| US12435104B2 (en) | 2019-07-25 | 2025-10-07 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| WO2021068866A1 (en) | 2019-10-10 | 2021-04-15 | Beigene, Ltd. | Heterocyclic compounds as sting modulators |
| WO2021177123A1 (ja) * | 2020-03-03 | 2021-09-10 | 国立大学法人富山大学 | 人工核酸 |
| IL298019A (en) | 2020-05-13 | 2023-01-01 | Massachusetts Inst Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
| CN115667274B (zh) | 2020-05-28 | 2025-04-29 | 百济神州有限公司 | 作为sting调节剂的杂环化合物 |
| WO2024211577A1 (en) | 2023-04-05 | 2024-10-10 | Massachusetts Institute Of Technology | Hybrid polymeric systems and methods of use thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1645561A1 (en) * | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EA027855B1 (ru) * | 2012-04-17 | 2017-09-29 | Гайлид Сайэнсиз, Инк. | Соединения и способы для противовирусной терапии |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| JP2016506408A (ja) * | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| EP2996472B1 (en) * | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| DK3233882T3 (da) * | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| CN108137641B (zh) * | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| IL280430B2 (en) * | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| RU2019122598A (ru) * | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные агонисты sting для лечения рака |
| WO2018118664A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
-
2018
- 2018-10-16 ES ES18797354T patent/ES2997757T3/es active Active
- 2018-10-16 WO PCT/US2018/056030 patent/WO2019079261A1/en not_active Ceased
- 2018-10-16 EP EP18797354.0A patent/EP3697801B1/en active Active
- 2018-10-16 US US16/849,091 patent/US11427610B2/en active Active
- 2018-10-16 CN CN201880072955.4A patent/CN111406063B/zh active Active
- 2018-10-16 KR KR1020207013709A patent/KR102747388B1/ko active Active
- 2018-10-16 JP JP2020542056A patent/JP7254821B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536897A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| JP2020532542A5 (enExample) | ||
| JP7602272B2 (ja) | Ｋｒａｓ関連がんを治療する方法 | |
| JP2020532529A5 (enExample) | ||
| KR101937501B1 (ko) | 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 | |
| JP2020532539A5 (enExample) | ||
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| JP2020529400A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| KR101671761B1 (ko) | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 | |
| IL319292A (en) | Cytotoxic imidazo[2,1-A]pyridine compounds and their use in therapy | |
| JP2014503567A5 (enExample) | ||
| JP2021513562A5 (enExample) | ||
| JP2014513704A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2010523681A5 (enExample) | ||
| KR20140059268A (ko) | 아미노-치환된 이미다조피리다진 | |
| JP2018534289A5 (enExample) | ||
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| HRP20220520T1 (hr) | Ciklički dinukleotidi kao agensi protiv raka | |
| JP2020527173A5 (enExample) |